Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059822 | 0.77 | FOLH1 (0.57) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL5054744 | 0.77 | FOLH1 (0.61) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL7608626 | 0.76 | FOLH1 (0.60) | FOLH1GRM3NAALAD2 | |
| SCHEMBL9814740 | 0.76 | FOLH1 (0.48) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL7608582 | 0.74 | CPA3 (0.50) | FOLH1CYP1A2NAALAD2 | |
| SCHEMBL9814887 | 0.74 | FOLH1 (0.61) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7839040 | 0.74 | FOLH1 (0.63) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL7611637 | 0.74 | FOLH1 (0.58) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL7618177 | 0.74 | FOLH1 (0.62) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7608459 | 0.72 | CPA3 (0.63) | FOLH1CYP1A2NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |